These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 15280099

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Role of nitric oxide in leukocyte-independent endothelial damage during experimental endotoxemia.
    Walther A, Barth C, Gebhard MM, Martin E.
    Shock; 2003 Sep; 20(3):286-91. PubMed ID: 12923503
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.
    Tam SH, Sassoli PM, Jordan RE, Nakada MT.
    Circulation; 1998 Sep 15; 98(11):1085-91. PubMed ID: 9736595
    [Abstract] [Full Text] [Related]

  • 8. Effect of the 21-aminosteroid tirilazad mesylate on leukocyte adhesion and macromolecular leakage during endotoxemia.
    Schmidt H, Schmidt W, Müller T, Böhrer H, Bach A, Gebhard MM, Martin E.
    Surgery; 1997 Mar 15; 121(3):328-34. PubMed ID: 9068675
    [Abstract] [Full Text] [Related]

  • 9. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA, Worley S, Veriabo NJ, Lance ET, Mack S, Schaible T, Weisman HF, Jordan RE.
    Circulation; 1997 Dec 02; 96(11):3860-6. PubMed ID: 9403608
    [Abstract] [Full Text] [Related]

  • 10. Role of platelet-activating factor in leukocyte-independent plasma extravasation and mast cell activation during endotoxemia.
    Walther A, Yilmaz N, Schmidt W, Bach A, Gebhard MM, Martin E, Schmidt H.
    J Surg Res; 2000 Oct 02; 93(2):265-71. PubMed ID: 11027469
    [Abstract] [Full Text] [Related]

  • 11. [Expression of inducible nitric oxide synthase in the carotid of rats after endothelial skinning: the effects of platelets and treatment with abciximab].
    González-Fernández F, Rodríguez-Feo JA, Farré J, Guerra J, Romero J, Gómez J, Rico L, Ayala R, Marcos P, Sánchez de Miguel L, Casado S, López-Farré A.
    Rev Esp Cardiol; 1999 Jun 02; 52(6):422-8. PubMed ID: 10373776
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.
    Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE.
    Circulation; 1998 May 05; 97(17):1680-8. PubMed ID: 9591761
    [Abstract] [Full Text] [Related]

  • 13. The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2).
    Schwarz M, Nordt T, Bode C, Peter K.
    Thromb Res; 2002 Aug 15; 107(3-4):121-8. PubMed ID: 12431477
    [Abstract] [Full Text] [Related]

  • 14. Effects of physostigmine on microcirculatory alterations during experimental endotoxemia.
    Peter C, Schmidt K, Hofer S, Stephan M, Martin E, Weigand MA, Walther A.
    Shock; 2010 Apr 15; 33(4):405-11. PubMed ID: 20407407
    [Abstract] [Full Text] [Related]

  • 15. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction.
    Neumann FJ, Zohlnhöfer D, Fakhoury L, Ott I, Gawaz M, Schömig A.
    J Am Coll Cardiol; 1999 Nov 01; 34(5):1420-6. PubMed ID: 10551687
    [Abstract] [Full Text] [Related]

  • 16. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ, Taatjes DJ, Sobel BE.
    Cardiovasc Res; 2000 Jan 14; 45(2):437-46. PubMed ID: 10728364
    [Abstract] [Full Text] [Related]

  • 17. Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.
    Bertram U, Moser M, Peter K, Kuecherer HF, Bekeredjian R, Straub A, Nordt TK, Bode C, Ruef J.
    J Thromb Thrombolysis; 2002 Dec 14; 14(3):197-203. PubMed ID: 12913399
    [Abstract] [Full Text] [Related]

  • 18. Time-dependent effect of clonidine on microvascular permeability during endotoxemia.
    Schmidt K, Hernekamp JF, Philipsenburg C, Zivkovic AR, Brenner T, Hofer S.
    Microvasc Res; 2015 Sep 14; 101():111-7. PubMed ID: 26177515
    [Abstract] [Full Text] [Related]

  • 19. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.
    Coller BS, Lang D, Scudder LE.
    Circulation; 1997 Feb 18; 95(4):860-7. PubMed ID: 9054743
    [Abstract] [Full Text] [Related]

  • 20. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
    Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf R, Lincoff AM.
    J Am Coll Cardiol; 2000 Aug 18; 36(2):381-6. PubMed ID: 10933346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.